Molina Healthcare Inc stocks have been trading up by 12.57 percent amid upbeat sentiment on robust Medicaid membership growth.
Click Here for a Millionaire's POV on Trading MOH
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Q1 2026 adjusted EPS of $2.35 beat expectations around $1.90–$1.94, while roughly $10.80B in revenue missed slightly and fell versus last year.
- Results showed sharply lower GAAP and adjusted earnings and notable membership losses, even as management stressed stable-to-favorable medical cost trends.
- Molina reaffirmed 2026 adjusted EPS of at least $5.00 and about $42B in premium revenue, implying a ~2% decline from 2025.
- Shares climbed about 6% to $152.65 after CMS finalized 2027 Medicare Advantage and Part D rates with an average 2.48% revenue increase.
- BofA raised its MOH price target to $152 but kept an Underperform rating, warning 2027 rates may still trail medical cost inflation.
Live Update At 12:32:22 EDT: On Thursday, April 23, 2026 Molina Healthcare Inc stock [NYSE: MOH] is trending up by 12.57%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Molina Healthcare, ticker MOH, is trading like a name caught between solid execution and real headwinds. The latest daily chart shows MOH ripping from the low $130s on 2026/03/30 to a close of $172.23 on 2026/04/23. That is a strong uptrend, with higher lows building from $131.47 to $139.38, then $147–$153, before the latest breakout candle.
Intraday on 2026/04/23, MOH opened at $164.76 and pushed as high as $177.87 before closing near the top of the range. That tells traders dip buyers were in control most of the day, absorbing profit-taking and squeezing shorts.
More Breaking News
- EVTL Stock Sinks As Vertical Aerospace Faces Funding And Legal Pressures
- MAS Stock Grinds Higher As Wall Street Resets Expectations
- ALAB Stock Extends Rally As Traders Track Tight Range
- CRML Stock Slides As Director Files Notable Share Sale
Fundamentally, Molina posted about $10.80B in Q1 revenue and adjusted EPS of $2.35, ahead of consensus even though revenue slipped and membership declined. Key ratios show a lean model: a price-to-sales near 0.18 and return on equity above 18% point to efficient use of capital, while debt-to-equity near 0.97 and a current ratio of 1.7 suggest leverage is manageable. For traders, that mix of earnings beat, modest valuation, and strong price momentum puts MOH firmly on breakout watch.
Why Traders Are Watching MOH Now
MOH is in the spotlight because the story is messy, but the tape is strong. Molina Healthcare’s Q1 2026 report showed declining revenue, sharply lower year-over-year earnings, and membership losses. On paper, that is not what growth traders want to see. Yet the company still delivered adjusted EPS of $2.35 versus expectations around $1.90–$1.94 and kept its 2026 guidance intact.
Molina reaffirmed at least $5.00 in adjusted EPS for 2026 and about $42B in premium revenue, which implies roughly a 2% step down from 2025. Management leaned hard on a “disciplined medical cost” message, pointing to a consolidated medical cost ratio near 91.1% and describing trends as stable-to-favorable. MOH also booked a non-cash impairment as it exits its Medicare Part D product to focus on higher-value dual-eligible members, signaling a shift toward business it believes carries better returns.
The macro backdrop turned more favorable too. When CMS finalized 2027 Medicare Advantage and Part D rates with an expected average 2.48% increase, managed care names, including Molina Healthcare, popped mid- to high-single digits. MOH jumped about 6% to $152.65 as traders read the decision as easing reimbursement risk and supporting future earnings.
Still, not everyone is all-in. BofA raised its MOH price target from $145 to $152 but kept an Underperform rating, arguing that the 2.48% rate bump likely trails medical cost inflation and keeps 2027 margin pressure on the table. Add in Molina’s signal that it will revisit 2026 guidance after the first half, and you have a classic trader setup: strong relief rally, solid near-term numbers, but lingering doubts about how much runway is left.
Conclusion
Molina Healthcare sits at an interesting crossroads for active traders. On one hand, MOH has delivered exactly what earnings-focused traders like to see: a clean EPS beat, reaffirmed guidance, and a regulatory win from CMS that lifts visibility on 2027 Medicare revenue. The stock’s move from the low $130s to the low $170s, with aggressive intraday buying on 2026/04/23, confirms that the market respects that combo.
On the other hand, the underlying fundamentals are not bulletproof. Molina Healthcare’s Q1 revenue and earnings declined year over year, membership shrank, and premium revenue guidance implies a modest contraction in 2026. Management’s exit from Medicare Part D and focus on dual-eligible members is a strategic pivot, but it is still a pivot born out of pressure. BofA’s Underperform rating on MOH, even with a higher price target, underlines that concern.
For short-term trading, MOH offers volatility, news catalysts, and a clear trend — the core ingredients momentum traders hunt. For longer-term positioning, the key checkpoints will be the upcoming Investor Day and the 1H 2026 guidance update. As Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.” As Tim Sykes likes to say, “The market doesn’t care about your opinion, only about price and volume — study the pattern, trade the reaction, and always, always manage your risk.” This coverage is for educational and research purposes only, and MOH remains a name to watch, not a promise.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.